Research in the field of radiopharmaceuticals is increasingly promoted by the widespread and growing interest in applying nuclear medicine procedures in both disease diagnosis and treatment. The production of radionuclides of medical interest is however a challenging issue. Along with the conventional techniques other innovative approaches are being investigated and, among those, the ISOLPHARM project is being developed at INFN-LNL (Istituto Nazionale di Fisica Nucleare – Laboratori Nazionali di Legnaro). Such technique foresees the employment of the SPES ISOL facility to produce isobarically pure Radioactive Ion Beams (RIBs), obtained thanks to electromagnetic mass separation and collected on appropriate substrates. The latter are successively recovered and dissolved, allowing thus the chemical separation and harvesting of the nuclides of interest, free from any isotopic contaminant. Although ISOLPHARM can be potentially employed for most of the routinely used medical radioisotopes, its innovation potential is better expressed considering its capability to provide carrier free unconventional nuclides, difficult to produce with state-of-art techniques, such as ¹¹¹Ag, a β^— emitter potentially interesting for therapeutic applications. Thus, in the framework of ISOLPHARM, INFN supported a two-years experiment, called ISOLPHARM_Ag, aimed at evaluating the feasibility of the production of a¹¹¹Ag labelled radiopharmaceutical. The ISOL production yields are estimated by computing intensive Monte Carlo codes, that require an appropriate custom Information Technology infrastructure. The presented work is focused on the first part of the production chain including the capability to extract, ionize, and collect stable Ag beams with SPES technologies. MC calculations were used to estimate the expected ¹¹¹Ag in-target yields, whereas experiments with stable Ag were performed to test the ionization, transport and collection of Ag beams.

对将核医学程序应用于疾病诊断和治疗的广泛和日益增长的兴趣日益促进了放射性药物领域的研究。然而，具有医学意义的放射性核素的生产是一个具有挑战性的问题。除了传统技术，其他创新方法也在研究之中，其中 INFN-LNL（Istituto Nazionale di Fisica Nucleare – Laboratori Nazionali di Legnaro）正在开发 ISOLPHARM 项目。这种技术预见了使用 SPES ISOL 设施生产等压纯放射性离子束 (RIB)，由于电磁质量分离而获得并收集在适当的基材上。后者依次被回收和溶解，从而允许对感兴趣的核素进行化学分离和收获，而没有任何同位素污染物。尽管 ISOLPHARM 可用于大多数常规使用的医用放射性同位素，但考虑到其提供无载体的非常规核素的能力，其创新潜力得到了更好的体现，这些核素难以用最先进的技术生产，例如¹¹¹ Ag，一种 β ^-发射体，可能对治疗应用感兴趣。因此，在 ISOLPHARM 的框架内，INFN 支持了一项为期两年的名为 ISOLPHARM_Ag 的实验，旨在评估生产¹¹¹ Ag 标记的放射性药物的可行性。ISOL 产量是通过计算密集型蒙特卡罗代码估算的，这需要适当的定制信息技术基础设施。所介绍的工作侧重于生产链的第一部分，包括使用 SPES 技术提取、电离和收集稳定银束的能力。MC 计算用于估计预期的¹¹¹目标中的银产率，而使用稳定银进行实验以测试银束的电离、传输和收集。